Key Pediatric Clinical Practice Guidelines in 2017

Antiemetics in Children

American Society of Clinical Oncology

Pediatric patients who are treated with high-emetic-risk antineoplastic agents should be offered a 3-drug combination of a 5-HT₃ receptor antagonist, dexamethasone, and aprepitant.

Pediatric patients who are treated with high-emetic-risk antineoplastic agents who are unable to receive aprepitant should be offered a 2-drug combination of a 5-HT₃ receptor antagonist and dexamethasone.

Pediatric patients who are treated with high-emetic-risk antineoplastic agents who are unable to receive dexamethasone should be offered a 2-drug combination of palonosetron and aprepitant.

References

• Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017 Jul 31. http://ascopubs.org/doi/full/10.1200/JCO.2017.74.4789

• Mulcahy N. New Antiemetic Guidelines Issued by ASCO. Medscape News & Perspective. Oncology. WebMD Inc. July 31, 2017. http://www.medscape.com/viewarticle/883608

Medscape © 2018 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Key Pediatric Clinical Practice Guidelines in 2017 - Medscape - Jan 10, 2018.